Abstract:
PURPOSE: A hyperbranched polymer, a fuel cell electrode including thereof, and a fuel cell including the electrode are provided to simply mass produce the polymer with an easy synthesizing process, and to improve the oxygen permeability, the durability, and the heat resistance of the electrode. CONSTITUTION: A hyperbranched polymer with the degree of branching of 0.05~1, contains a dendritic unit marked with chemical formula 1, a linear unit marked with chemical formula 2, a terminal unit marked with chemical formula 3. In the chemical formulas, R is selected from the group consisting of fluorine, a fluorinated alkyl group with C1~C20, a fluorinated aryl group with C6~C20, a fluorinated heteroaryl group with C2~C20, a fluorinated cycloalkyl group with C6~C20, and a fluorinated heterocyclic group with C2~C20.
Abstract:
PURPOSE: A hyperbranched polymer with excellent heat resistance is provided to manufacture a fuel cell with improved lifetime property and cell properties. CONSTITUTION: A hyperbranched polymer is the product obtained through condensation polymerization of a composition for forming the hyperbranched polymer consisting of a diisocyanate-based compound represented by chemical formula 1 and a dihydroxy amine-based compound represented by chemical formula 2. In chemical formula 1, A is a substituted or unsubstituted C1-C30 alkylene group, substituted or unsubstituted C2-C30 alkenylene group, substituted or unsubstituted C2-C30 alkynylene group, substituted or unsubstituted C6-C30 arylene group, substituted or unsubstituted C2-C30 heteroarylene group, substituted or unsubstituted C4-C30 carbon ring group, or substituted or unsubstituted C6-C30 condensed polycyclic group.
Abstract:
PURPOSE: A compound is provided to ensure excellent heat resistance and phosphoric acid resistance and to obtain a fuel cell with an improved lifetime property and cell performance when applied to the electrode and the electrolyte film for the fuel cell. CONSTITUTION: A compound is a polymerization product of a composition that contains a diisocyanate-based compound represented by chemical formula 1 below and an aromatic polyol represented by chemical formula 2, wherein A1 and A2 are each independently a substituted or unsubstituted C1-C30 alkylene group, a substituted or unsubstituted C2-C30 alkenylene group, a substituted or unsubstituted C2-C30 alkynylene group, a substituted or unsubstituted C6-C30 arylene group, a substituted or unsubstituted C2-C30 heteroarylene group, a substituted or unsubstituted C4-C30 carbon cyclic group, or a substituted or unsubstituted C6-C30 condensed polycyclic group; m is 0 or 1; R1 is a hydrogen atom or -P(-O)RR'; R and R' are each independently a hydrogen atom, a C1-C30 alkyl group, or a C6-C30 aryl group; and L is represented by chemical formula 1A.
Abstract:
본 발명에 따른 췌장소도의 표면개질 방법은, 이중기능성을 갖는 고차구조의 PEG를 췌장소도의 표면에 1차 코팅하여 보다 효과적으로 면역반응을 감소시키고, 상기 1차 코팅의 표면에 생체활성 복합체를 2차 코팅함으로써 항혈전성 효과를 유도하여, 췌장소도를 간문맥에 이식 시 발생하는 초급성혈액매개성염증반응(Instant blood mediated inflammatory reaction, IBMIR)을 보다 효과적으로 저해함으로써 췌장소도의 생존기간을 늘릴 수 있으므로, 췌장소도 이식의 전처리 과정에 유용하게 사용될 수 있다.
Abstract:
본 발명은 분비 신호 펩타이드가 연결된 엑센딘-4를 도입한 췌장소도세포 클러스터 및 이를 이용한 당뇨병 치료방법에 관한 것으로, 보다 상세하게는 인슐린 분비능이 향상되고 이식 시 세포의 괴사율을 감소시키고 면역 억제성을 향상시키는 분비 신호 펩타이드가 연결된 엑센딘-4를 도입한 췌장소도세포 클러스터에 관한 것이다. 본 발명은 췌장소도 단일세포에 렌티바이러스(Lentivirus) 벡터를 이용하여 분비 신호 펩타이드(secretion signal peptide)가 연결된 엑센딘-4 유전자(Exendin-4)를 도입함으로써, 유전자의 전달 효율을 높여 인슐린 분비능의 향상을가져오고, 세포의 크기를 조절하여 이식 시 발생할 수 있는 세포의 괴사율을 감소시키고 최종적으로 생체적합성 고분자 물질을 이용한 표면 개질을 통해 면역 억제성까지 향상 효과를 가지므로 당뇨병 치료에 유용하게 사용될 수 있다.
Abstract:
PURPOSE: A method for modifying the surface of pancreatic islets is provided to effectively reduce immune response and to induce antithrombogenicity effect. CONSTITUTION: A method for modifying the surface of pancreatic islet comprises: a step of activating PEG or derivatives thereof for conjugation of PEG or derivatives thereof on the surface of the pancreatic islet; a step of conjugating the activated PEG or derivatives thereof with an amine group on the surface; and a step of conjugating the terminal function groups of the PEG or derivatives with the bioactive complex. The bioactive complex is conjugated with heparin or derivatives thereof, and bioactivation materials. [Reference numerals] (AA) Pancreatic islet cells; (BB) Heparin catechol; (CC) 8-armed star shaped PEG